XuanZhu Bio-B Added to Hang Seng Composite Index, Potential Candidate for Stock Connect

Stock News02-13 19:36

On February 13, Hang Seng Indexes Company announced the results of its quarterly review of the Hang Seng Index Series as of December 31, 2025. XuanZhu Bio-B (02575) has been included in the Hang Seng Composite Index. The changes will take effect after the market close on Friday, March 6, 2026, and will be implemented starting Monday, March 9, 2026. Following this, the Shanghai and Shenzhen stock exchanges are expected to adjust the list of eligible stocks under the Hong Kong Stock Connect program accordingly. According to a CICC research report, XuanZhu Bio-B is likely to be added to the Stock Connect scheme, as it meets a range of criteria including market capitalization, liquidity, and listing duration. On December 7, 2025, the National Healthcare Security Administration released the updated National Reimbursement Drug List for 2025. XuanZhu Bio-B’s self-developed Class 1 innovative drug, the CDK4/6 inhibitor Piroxiclib Tablets, was successfully included in the list, providing new reimbursement benefits for patients with advanced breast cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130834822?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 19:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130834822","market":"sh","top_or_hot":-1,"title":"XuanZhu Bio-B Added to Hang Seng Composite Index, Potential Candidate for Stock Connect","media":"Stock News","content":"<p>On February 13, Hang Seng Indexes Company announced the results of its quarterly review of the Hang Seng Index Series as of December 31, 2025. XuanZhu Bio-B (02575) has been included in the Hang Seng Composite Index. The changes will take effect after the market close on Friday, March 6, 2026, and will be implemented starting Monday, March 9, 2026. Following this, the Shanghai and Shenzhen stock exchanges are expected to adjust the list of eligible stocks under the Hong Kong Stock Connect program accordingly. According to a CICC research report, XuanZhu Bio-B is likely to be added to the Stock Connect scheme, as it meets a range of criteria including market capitalization, liquidity, and listing duration. On December 7, 2025, the National Healthcare Security Administration released the updated National Reimbursement Drug List for 2025. XuanZhu Bio-B’s self-developed Class 1 innovative drug, the CDK4/6 inhibitor Piroxiclib Tablets, was successfully included in the list, providing new reimbursement benefits for patients with advanced breast cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XuanZhu Bio-B Added to Hang Seng Composite Index, Potential Candidate for Stock Connect</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanZhu Bio-B Added to Hang Seng Composite Index, Potential Candidate for Stock Connect\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-13 19:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On February 13, Hang Seng Indexes Company announced the results of its quarterly review of the Hang Seng Index Series as of December 31, 2025. XuanZhu Bio-B (02575) has been included in the Hang Seng Composite Index. The changes will take effect after the market close on Friday, March 6, 2026, and will be implemented starting Monday, March 9, 2026. Following this, the Shanghai and Shenzhen stock exchanges are expected to adjust the list of eligible stocks under the Hong Kong Stock Connect program accordingly. According to a CICC research report, XuanZhu Bio-B is likely to be added to the Stock Connect scheme, as it meets a range of criteria including market capitalization, liquidity, and listing duration. On December 7, 2025, the National Healthcare Security Administration released the updated National Reimbursement Drug List for 2025. XuanZhu Bio-B’s self-developed Class 1 innovative drug, the CDK4/6 inhibitor Piroxiclib Tablets, was successfully included in the list, providing new reimbursement benefits for patients with advanced breast cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1130834822","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130834822","pubTimestamp":1770982579,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On February 13, Hang Seng Indexes Company announced the results of its quarterly review of the Hang Seng Index Series as of December 31, 2025. XuanZhu Bio-B (02575) has been included in the Hang Seng...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","HSCI":"恒生综合指数","VXUS":"国际股票ETF-Vanguard","02575":"轩竹生物-B","VT":"世界全股市ETF-Vanguard","BK4588":"碎股","BK1191":"制药"},"translate_title":"轩竹生物-B加入恒生综合指数沪股通潜在候选","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"VT":1,"02575":1,"HSCI":1},"content_text":"On February 13, Hang Seng Indexes Company announced the results of its quarterly review of the Hang Seng Index Series as of December 31, 2025. XuanZhu Bio-B (02575) has been included in the Hang Seng Composite Index. The changes will take effect after the market close on Friday, March 6, 2026, and will be implemented starting Monday, March 9, 2026. Following this, the Shanghai and Shenzhen stock exchanges are expected to adjust the list of eligible stocks under the Hong Kong Stock Connect program accordingly. According to a CICC research report, XuanZhu Bio-B is likely to be added to the Stock Connect scheme, as it meets a range of criteria including market capitalization, liquidity, and listing duration. On December 7, 2025, the National Healthcare Security Administration released the updated National Reimbursement Drug List for 2025. XuanZhu Bio-B’s self-developed Class 1 innovative drug, the CDK4/6 inhibitor Piroxiclib Tablets, was successfully included in the list, providing new reimbursement benefits for patients with advanced breast cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130834822","isCrawlerRequest":true}